AGEN (Agenus) Cyclically Adjusted PB Ratio: (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGEN Agenus Inc AGEN
43 GF Score
Price $7.16
GF Value $3.78
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Agenus Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agenus  (NAS:AGEN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Agenus Cyclically Adjusted PB Ratio Related Terms


Agenus Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Agenus's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agenus Cyclically Adjusted PB Ratio Chart

Agenus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Agenus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AGEN vs FULC, IRD, TTRX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Agenus's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's Cyclically Adjusted PB Ratio falls into.


AGEN
43GF Score
Agenus Inc AGEN
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agenus Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Agenus's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Agenus's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-4.448/333.9520*333.9520
=-4.448

Current CPI (Jun. 2026) = 333.9520.

Agenus Quarterly Data

Book Value per Share CPI Adj_Book
201609 -4.830 241.428 -6.681
201612 -8.913 241.432 -12.329
201703 1.804 243.801 2.471
201706 -3.510 244.955 -4.785
201709 -10.346 246.819 -13.998
201712 -14.910 246.524 -20.198
201803 -21.957 249.554 -29.383
201806 -20.271 251.989 -26.864
201809 -22.036 252.439 -29.151
201812 -28.745 251.233 -38.209
201903 -17.308 254.202 -22.738
201906 -22.910 256.143 -29.869
201909 -29.075 256.759 -37.816
201912 -32.703 256.974 -42.499
202003 -23.995 258.115 -31.045
202006 -25.507 257.797 -33.042
202009 -20.986 260.280 -26.926
202012 -20.772 260.474 -26.632
202103 -17.411 264.877 -21.951
202106 -21.941 271.696 -26.969
202109 3.382 274.310 4.117
202112 2.681 278.802 3.211
202203 1.179 287.504 1.369
202206 0.242 296.311 0.273
202209 -1.382 296.808 -1.555
202212 -4.011 296.797 -4.513
202303 -3.427 301.836 -3.792
202306 -5.072 305.109 -5.551
202309 -6.771 307.789 -7.347
202312 -8.131 306.746 -8.852
202403 -9.595 312.332 -10.259
202406 -11.422 314.175 -12.141
202409 -13.481 315.301 -14.278
202412 -13.809 315.605 -14.612
202503 -12.869 319.799 -13.439
202506 -11.818 322.561 -12.235
202509 -8.354 324.800 -8.589
202512 -7.676 324.054 -7.910
202603 -5.743 330.213 -5.808
202606 -4.448 333.952 -4.448

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Agenus (AGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Agenus stock appears to be overvalued. The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78. GuruFocus considers Agenus to be Significantly Overvalued.

Key valuation signals for AGEN:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
  • GF Score™: 43/100 with 12 warning signs

No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agenus Business Description

Other Exchanges AJ8:Germany
Address 3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score

Get the complete analysis for AGEN

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.16
Price
$3.78
GF Value